The study included COVID-19 vaccines from Pfizer, Moderna and AstraZeneca, but did not include Johnson & Johnson’s.
Researchers found that the risk of developing cerebral venous thrombosis — a type of rare blood clot that was discovered in small numbers of people vaccinated with both Johnson & Johnson’s and AstraZeneca’s COVID-19 vaccines — was eight to 10 times greater among adults with COVID-19 than among anyone receiving either Pfizer, Moderna or AstraZeneca’s shot.
Researchers looked at data from 513,000 people who were diagnosed with COVID-19 between January 2020 and March 25, 2021. The study — conducted by different researchers than those from the University of Oxford that developed AstraZeneca’s vaccine — didn’t shed light on the causes of the clots, the Journal reported.
AstraZeneca’s vaccine hasn’t been approved in the U.S. but has been in Europe, where several countries have restricted its use after finding some instances of people developing cerebral venous thrombosis.
The study has not been peer-reviewed, the Journal noted.
Read the full article here.
More articles on pharmacy:
J&J vaccine pause continues: Why Fauci thinks it could be a good thing
Moderna vaccine 90% effective after 6 months, study shows
9 things to know about the J&J, AstraZeneca COVID-19 vaccines & blood clots
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
